Skye Bioscience, Inc.SKYENASDAQ

Revenue (LTM)

Net Income (LTM)

$-56M

-110.5% YoY

Free Cash Flow

$-43M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.0B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	0	0
Gross Profit	0	0	0	0	-1
Operating Income	-8	-18↓133.3%	-35↓89.7%	-30↑13.1%	-58↓92.6%
Net Income	-9	-19↓128.6%	-38↓93.2%	-27↑29.4%	-56↓110.5%
EBITDA	-8	-19↓142.2%	-37↓95.9%	-25↑30.9%	-57↓127.1%
EPS Diluted	-5.00	-8.77↓75.4%	-5.37↑38.8%	-0.73↑86.4%	-1.41↓93.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	9	1↓86.1%	1↑1.0%	68↑5345.1%	6↓91.4%
Total Current Assets	10	9↓7.0%	12↑30.3%	71↑507.9%	27↓61.7%
Total Assets	10	9↓7.5%	12↑31.1%	73↑509.4%	28↓61.1%
Total Current Liabilities	4	12↑209.8%	14↑14.7%	4↓68.8%	8↑89.1%
Total Liabilities	4	12↑203.7%	14↑16.1%	5↓67.2%	8↑79.7%
Total Equity	6	-3↓151.3%	-2↑29.1%	68↑3296.9%	20↓70.6%
Total Debt	2	2↓7.2%	5↑132.8%	0↓90.1%	0↓39.9%
Net Debt	-7	1↑110.8%	3↑355.1%	-68↓2123.3%	-6↑91.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-6	-13↓96.8%	-14↓9.5%	-25↓80.9%	-43↓70.6%
Capital Expenditure	-0	-0↑69.1%	-0↑55.3%	-2↓12681.1%	-0↑99.6%
Free Cash Flow	-7	-13↓94.5%	-14↓9.3%	-27↓92.2%	-43↓60.5%
Stock-Based Comp	1	1↓27.6%	1↑57.0%	8↑742.3%	8↓6.6%
Net Change in Cash	7	-8↓218.8%	9↑217.4%	58↑539.1%	-63↓207.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance